Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): Results from cancer and leukemia group B study 8461 and review of the literature

Cancer

Volumn 101, Issue 6, 2004, Pages 1420-1427

  Blum, William ^a   Mrózek, Krzysztof ^a   Ruppert, Amy S ^a,b   Carroll, Andrew J ^c   Rao, Kathleen W ^d   Pettenati, Mark J ^e   Anastasi, John ^f   Larson, Richard A ^f   Bloomfield, Clara D ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b Cancer and Leukemia Group B Statistical Center   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

Author keywords

Adult acute myeloid leukemia; Cytogenetics; Stem cell transplantation; T(6; 11)(q27; q23)

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AFRICAN AMERICAN; AGE; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CYTOGENETICS; DATA BASE; FEMALE; FRANCE; GINGIVA HYPERTROPHY; HUMAN; HUMAN CELL; MALE; MEDICAL LITERATURE; PRIORITY JOURNAL; REVIEW; UNITED KINGDOM; UNITED STATES;

ACUTE DISEASE; ADULT; AGED; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 6; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 4444226107     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20489     Document Type: Review

References (38)

1. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322-2333.
2. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood. 2000;96:4075-4083.
3. Byrd JC, Mrózek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002; 100;4325-4336.
4. Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001.
5. Rowley JD. The role of chromosome translocations in leukemogenesis. Semin Hematol. 1999;36 Suppl 7:59-72.
6. Mrózek K, Heinonen K, Bloomfield CD. Clinical importance of cytogenetics in acute myeloid leukaemia. Best Pract Res Clin Haematol. 2001;14:19-47.
7. Mitelman F, Johansson B, Mertens F, editors. Mitelman database of chromosome aberrations in cancer [database online]. Available from URL: http://cgap.nci.nih.gov/Chromosomes/Mitelman [accessed Jan 30, 2004].
8. Mrozek K, Heinonen K, Lawrence D, et al. Adult patients with de novo acute myeloid leukemia and t(9;11)(p22;q23) have a superior outcome to patients with other translocations involving band 11q23: a Cancer and Leukemia Group B study. Blood. 1997;90:4532-4538.
9. Rubnitz JE, Raimondi SC, Tong X, et al. Favorable impact of the t(9;11) in childhood acute myeloid leukemia. J Clin Oncol. 2002;20:2302-2309.
10. Yunis JJ, Bloomfield CD, Ensrud K. All patients with acute nonlymphocytic leukemia may have a chromosomal defect. N Engl J Med. 1981;305:135-139.
11. Mayer RJ, Schiffer CA, Peterson BA, et al. Intensive postremission therapy in adults with acute nonlymphocytic leukemia with ara-C by continuous infusion or bolus administration: preliminary results of a CALGB Phase I study. Semin Oncol 1985;12 Suppl 3:84-90.
12. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med. 1994;331:896-903.
13. Moore JO, Powell B, Velez-Garcia E, et al. A comparison of sequential non-cross-resistant therapy or Ara-C consolidation following complete remission in adult patients < 60 years with acute myeloid leukemia: CALGB 9222 [abstract]. Proc Am Soc Clin Oncol. 1997;16:14a.
14. Kolitz JE, George SL, Dodge RK, et al. Dose escalation studies of Ara-C (A), daunorubicin (D) and etoposide (E) with and without multidrug resistance (MDR) modulation with PSC-833 (P) in untreated adults with acute myeloid leukemia (AML) < 60 years: final induction results of CALGB 9621 [abstract]. Blood. 2001;98:461a.
15. Baer MR, George SL, Dodge RK, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B study 9720. Blood. 2002;100:1224-1232.
16. Bennett JM, Catovsky D, Daniel M-T, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:620-625.
17. Mitelman F, editor. ISCN 1995: an international system for human cytogenetic nomenclature. Basel: Karger, 1995.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
19. Bloomfield CD, Archer BCJ, Mrózek K, et al. 11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer. 2002;33: 362-378.
20. Martineau M, Berger R, Lillington DM, Moorman AV, Seeker-Walker LM. The t(6;11)(q27;q23) translocation in acute leukemia: a laboratory and clinical study of 30 cases. Leukemia. 1998;12:788-791.
21. Mitterbauer G, Zimmer C, Pirc-Danoewinata H, et al. Monitoring of minimal residual disease in patients with MLL-AF6-positive acute myeloid leukaemia by reverse transcriptase polymerase chain reaction. Br J Haematol 2000;109: 622-628.
22. Giugliano E, Rege-Cambrin G, Scaravaglio P, et al. MLL-AF6 fusion resulting from a new three-way translocation t(6; 11;7) in a patient with acute myeloid leukemia. Leukemia. 2001;15:1674-1676.
23. Kobayashi H, Espinosa R III, Thirman MJ, et al. Do terminal deletions of 11q23 exist? Identification of undetected translocations with fluorescence in situ hybridization. Genes Chromosomes Cancer. 1993;7:204-208.
24. Takatsuki H, Yufu Y, Tachikawa Y, Uike N. Monitoring minimal residual disease in patients with MLL-AF6 fusion transcript-positive acute myeloid leukemia following allogeneic bone marrow transplantation. Int J Hematol. 2002;75:298-301.
25. Prasad R, Gu Y, Alder H, et al. Cloning of the ALL-1 fusion partner, the AF-6 gene, involved in acute myeloid leukemias with the t(6;11) chromosome translocation. Cancer Res. 1993;53:5624-5628.
26. Felix CA, Hosier MR, Slater DJ, et al. MLL genomic breakpoint distribution within the breakpoint cluster region in de novo leukemia in children. J Pediatr Hematol Oncol. 1998; 20:299-308.
27. Cahn J-Y, Labopin M, Schattenberg A, et al. Allogeneic bone marrow transplantation for acute leukemia in patients over the age of 40 years. Leukemia. 1997;11:416-419.
28. Ringdén O, Horowitz MM, Gale RP, et al. Outcome after allogeneic bone marrow transplant for leukemia in older adults. JAMA. 1993;270:57-60.
29. Ringdén O, Labopin M, Bacigalupo A, et al. Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. J Clin Oncol. 2002;20:4655-4664.
30. de la Cámara R, Alonso A, Steegmann JL, et al. Allogeneic hematopoietic stem cell transplantation in patients 50 years of age and older. Haematologica. 2002;87:965-972.
31. Ferrant A, Labopin M, Frassoni F, et al. Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Blood. 1997;90:2931-2938.
32. Burnett AK, Wheatley K, Goldstone AH, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukemia at differing risk of relapse: results of the UK MRC 10 trial. Br J Haematol. 2002;118:385-400.
33. Chalandon Y, Barnett MJ, Horsman DE, et al. Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant. 2002;8: 435-443.
34. Garrido SM, Bryant E, Appelbaum FR. Allogeneic stem cell transplantation for relapsed and refractory acute myeloid leukemia patients with 11q23 abnormalities. Leuk Res. 2000; 24:481-486.
35. Bower M, Parry P, Carter M, et al. Prevalence and clinical correlations of MLL gene rearrangements in AML-M4/5. Blood. 1994;84:3776-3780.
36. Jonveaux P, Hillion J, Bernard O, et al. Distinct MLL gene rearrangements associated with successive acute monocytic and lymphoblastic leukemias in the same patient. Leukemia. 1994;8:2224-2227.
37. Löwenberg B, Hagemeijer A, Swart K. Karyotypically distinct subpopulations in acute leukemia with specific growth requirements. Blood. 1982;59:641-645.
38. Tagawa M, Tokunaga K, Kuriyama K, et al. [Marked dysmyelopoiesis after induction chemotherapy in a case of acute myelomonocytic leukemia (M4) with t(6;11)]. Rinsho Ketsueki. 1989;30:232-238.